Growth of advanced therapies (ATMP) and the impact on pharmaceutical logistics

Advanced therapies, known by the acronym ATMP (Advanced Therapy Medicinal Products), have been gaining important ground in the development of modern medicine. But with the expansion of treatments based on gene therapy, cell therapies and biologics, there is also a growing demand for specialized pharmaceutical logistics, with a validated cold chain, precise traceability and safe transport.

What are advanced therapies (ATMP) and why are they booming?

MPTAs include medicines and treatments that use cutting-edge technologies, such as

• gene therapy,
• cell therapies (e.g. T cells),
• complex biologicals and precision therapies.

However, this type of treatment represents the future of medicine, targeting rare diseases, personalized treatments and highly efficient therapies. As a result, there is a continuous growth in clinical research and the production of products that require extreme logistical care, which increases the role of specialized pharmaceutical logistics.

Current data and overview of the ATMP market

Despite the scarcity of recent public reports with consolidated data (2024), the ATMP sector is often cited in market analyses as one of the segments with the greatest potential for global growth over the next decade.

However, projections indicate that the demand for biologics, cell therapies and biotech drugs will continue to evolve, especially in emerging markets and regions with expanding clinical research.

Why ATMPs require specialized logistics

Advanced therapy drugs and treatments often have strict technical requirements, for example:

• storage at controlled temperatures (“cold chain”), sometimes in ultra-low ranges,
• continuous tracking, with temperature monitoring, data loggers and regulatory documentation,
• careful, fast and safe transportation, to guarantee the integrity of the product all the way to its final destination,
• compliance with health and regulatory standards, especially in global or export/import contexts.

In addition, these requirements place logistics as an essential part of therapeutic efficacy, it's not just transportation, it's a guarantee of clinical integrity.

FIC Company's role in the new era of advanced therapies

With a focus on robust technical solutions, FIC Company is prepared to meet the growing demands of ATMP. We offer:

• qualified and controlled storage;
• validated cold chain for sensitive biologicals;
• secure transportation with 24/7 traceability;
• experience in logistics for clinical research and biotechnology;
• regulatory and operational support for the import and distribution of complex therapies.

Our expertise positions FIC as a reliable partner for pharmaceutical companies, laboratories, research centers and healthcare institutions operating with ATMP.

Opportunities and challenges in Brazil and LATAM

The expansion of advanced therapies offers opportunities for the Latin American market: cost reduction, access to innovative treatments and scientific development.
But it also brings challenges, such as

• the need for advanced logistics infrastructure;
• import/export regulations;
• traceability and climate control requirements;
• raising awareness among stakeholders of the importance of specialized logistics.

In this scenario, logistics operators are key to ensuring that the benefits of innovation arrive safely and efficiently.

Recommendations for companies working with ATMP

For those who manufacture, import or distribute ATMP, it's worth considering:

• hiring a specialized logistics chain with cold chain capabilities;
• continuous monitoring and traceability systems;
• auditing and certification of storage and transportation;
• integrated logistics planning from origin to final destination;
• regulatory documentation and compliance with health standards.

The advance of advanced therapies and the future of pharmaceutical logistics

The growth of advanced therapies (ATMP) represents a major transformation in the pharmaceutical sector and in global medicine. With it comes a high demand for specialized logistics, not just for transportation, but to guarantee the integrity, safety and compliance of treatments.
In addition, FIC is positioning itself as a strategic partner to meet the demands of this new scenario, offering complete and technical solutions for companies, laboratories and research centers.
The union between therapeutic innovation and logistical excellence is the way to bring more health, responsibly and efficiently, to patients and the industry.